Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia
Objective: To analyse the clinic characteristics, risk factors and evolution of the first cohort of hospitalised patients with confirmed infection by COVID-19 in 5 Colombian institutions. Materials and methods: Is a retrospective observational study of consecutive hospitalized patients with a diagnosis of COVID-19 confirmed from March 01 to May 30, 2020 in Colombia. Results: A total of 44 patients were included. The median age was 62 years. 43.2% had a history of smoking, while 69.8% were overweight or obese. 88.6% had at least one comorbidity and 52.3% had three or more comorbidities. Hypertension and dyslipidaemia were the most frequent comorbidities (40.9% and 34.1%, respectively). The 30-day mortality rate was 47.7% with a median of 11 days. The composite outcome occurred in the 36.4%. The biomarkers associated with mor-tality risk included troponin higher than 14 ng/L (RR: 5.25; 95% CI 1.37-20.1, p = 0.004) and D-dimer higher than 1000 ng/ml (RR: 3.0; 95% CI 1.4-6.3, p = 0.008). Conclusions: The clinical course of SARS-CoV-2 infection in hospitalized Colombian was characterised by a more advanced stage of the infection..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Infectio - 25(2021), 4, Seite 262-269 |
| Sprache: |
Englisch ; Spanisch |
|---|
| Beteiligte Personen: |
Nancy Yomayusa-Gonzalez [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Covid-19 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
DOAJ012189707 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ012189707 | ||
| 003 | DE-627 | ||
| 005 | 20230502143917.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230225s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)DOAJ012189707 | ||
| 035 | |a (DE-599)DOAJ4b21507fc65c424eb7e7d37f38c9e69b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a spa | ||
| 050 | 0 | |a RM1-950 | |
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Nancy Yomayusa-Gonzalez |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical course, biomarkers, management and outcomes of patients hospitalised due to COVID-19 in Colombia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objective: To analyse the clinic characteristics, risk factors and evolution of the first cohort of hospitalised patients with confirmed infection by COVID-19 in 5 Colombian institutions. Materials and methods: Is a retrospective observational study of consecutive hospitalized patients with a diagnosis of COVID-19 confirmed from March 01 to May 30, 2020 in Colombia. Results: A total of 44 patients were included. The median age was 62 years. 43.2% had a history of smoking, while 69.8% were overweight or obese. 88.6% had at least one comorbidity and 52.3% had three or more comorbidities. Hypertension and dyslipidaemia were the most frequent comorbidities (40.9% and 34.1%, respectively). The 30-day mortality rate was 47.7% with a median of 11 days. The composite outcome occurred in the 36.4%. The biomarkers associated with mor-tality risk included troponin higher than 14 ng/L (RR: 5.25; 95% CI 1.37-20.1, p = 0.004) and D-dimer higher than 1000 ng/ml (RR: 3.0; 95% CI 1.4-6.3, p = 0.008). Conclusions: The clinical course of SARS-CoV-2 infection in hospitalized Colombian was characterised by a more advanced stage of the infection. | ||
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a risk factors | |
| 650 | 4 | |a mortality | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 773 | 0 | 8 | |i In |t Infectio |d Asociación Colombiana de Infectología, 2018 |g 25(2021), 4, Seite 262-269 |w (DE-627)DOAJ000064378 |x 01239392 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:4 |g pages:262-269 |
| 856 | 4 | 0 | |u https://doi.org/10.22354/in.v25i4.958 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/4b21507fc65c424eb7e7d37f38c9e69b |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0123-9392 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 4 |h 262-269 | ||